分子证据支持MEK抑制剂疗法在NF1伪关节炎
Nandina Paria1, Ila Oxendine1, David Podeszwa2,3
1Center for Translational Research, Scottish Rite for Children, Dallas, Texas.
The Journal of bone and joint surgery. American volume
|April 1, 2025
概括
MEK 抑制剂在患有神经纤维素瘤类型1 (NF1) 的儿童中治疗骨折伪骨方面表现有前途. 这项研究发现,这些药物挽救了关键基因表达,与NF1伪样本的骨愈合有关.
科学领域:
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
- 儿科整形医生 儿科整形医生
背景情况:
- 神经纤维素瘤类型1 (NF1) 是一种遗传性疾病.
- NF1使儿童易受骨折伪骨折 (不愈合的骨折) 的影响.
- MEK 抑制剂已被批准用于 NF1 相关的恶性瘤,但它们在伪骨瘤中的作用尚未被探索.
研究的目的:
- 调查NF1相关骨折伪的分子基础.
- 评估MEK抑制剂在治疗这些疾病中的治疗潜力.
主要方法:
- 培养了NF1伪骨和对照骨的原始细胞.
- 细胞被用MEK抑制剂 (特拉美提尼布,塞卢美提尼布) 或载体治疗.
- 分析了基因表达 (RNAseq) 和信号通路激活 (西部斑点).
主要成果:
- NF1伪样本显示,对于骨质母细胞分化和骨发育至关重要的基因的表达减少.
- 使用MEK抑制剂治疗显著挽救了这些基因表达模式.
- 使用MEK抑制剂治疗导致MEK/ERK (MAPK) 途径激活减少.
结论:
- 鉴定了NF1骨折伪骨中对MEK抑制有反应的分子特征.
- MEK 抑制剂可能代表了一种新的治疗策略,用于促进 NF1 患者骨折伪硬骨的愈合.
更多相关视频
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
1.2K
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
1.7K
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
